KILITCH — Kilitch Drugs (India) Balance Sheet
0.000.00%
- IN₹6.52bn
- IN₹6.41bn
- IN₹1.98bn
- 57
- 31
- 83
- 62
Annual balance sheet for Kilitch Drugs (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 488 | 572 | 591 | 690 | 593 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 260 | 430 | 566 | 658 | 883 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 804 | 1,141 | 1,264 | 1,460 | 1,739 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 734 | 464 | 474 | 481 | 928 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,032 | 2,098 | 2,195 | 2,401 | 3,128 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 733 | 693 | 689 | 642 | 843 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 760 | 708 | 679 | 638 | 1,105 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 1,271 | 1,391 | 1,516 | 1,763 | 2,023 |
| Total Liabilities & Shareholders' Equity | 2,032 | 2,098 | 2,195 | 2,401 | 3,128 |
| Total Common Shares Outstanding |